Home
Our Business
Public Equity

EG Capital Advisors' most recent new venture is the EG Life-Sciences Fund 1 which it launched in May 2017 jointly with 4BIO Capital Partners, a London based investment firm specialising in life sciences. The fund invests in listed biotech companies developing gene and cell therapy technologies which are at the clinical testing stage. Our view is that by carefully selecting companies developing innovative treatments with significant commercial potential we can deliver venture capital-style returns with public market liquidity.

EG Capital Advisors Cayman Islands manages the Group’s EG Life Sciences Fund.